Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 4/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.43 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.42 |
| ▸ | RPS6KA5 | O75582 | 2/20 | 0.40 |
| ▸ | RPS6KA4 | O75676 | 2/20 | 0.40 |
| ▸ | CES1 | P23141 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.37 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.37 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.37 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.37 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.37 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 3/20 | 0.36 |
| ▸ | CD38 | P28907 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | PGR | P06401 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3704906 | 0.89 | MEN1 (0.48) | MEN1KMT2AGABRA1CES1ALDH1A1 | |
| SCHEMBL7595027 | 0.87 | MAPT (0.41) | MEN1KMT2ARPS6KA5RPS6KA4ALDH1A1 | |
| SCHEMBL594070 | 0.85 | MAPT (0.41) | RPS6KA5RPS6KA4ALDH1A1PSEN1PSEN2 | |
| SCHEMBL7591325 | 0.82 | HPGD (0.47) | MEN1KMT2AALDH1A1CYP3A4MAPT | |
| SCHEMBL7590764 | 0.82 | ALDH1A1 (0.41) | MEN1KMT2AGABRA1RPS6KA5RPS6KA4 | |
| SCHEMBL7591287 | 0.81 | MEN1 (0.43) | MEN1KMT2AGABRA1RPS6KA5CES1 | |
| SCHEMBL7592088 | 0.79 | RPS6KA5 (0.48) | MEN1KMT2ARPS6KA5RPS6KA4ALDH1A1 | |
| SCHEMBL7587648 | 0.77 | MEN1 (0.47) | MEN1KMT2ACES1ALDH1A1PSEN1 | |
| SCHEMBL18890216 | 0.76 | GABRA1 (0.37) | MEN1KMT2AGABRA1CES1ALDH1A1 | |
| SCHEMBL7591678 | 0.73 | CD38 (0.38) | MEN1KMT2ARPS6KA5RPS6KA4ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9938259-B2 | Therapeutic compositions and related methods of use | AGIOS PHARMACEUTICALS, INC. (US) | 2018-04-10 | — | — | US | disclosed |
| US-9938259-B2 | Therapeutic compositions and related methods of use | AGIOS PHARMACEUTICALS, INC. (US) | 2018-04-10 | — | — | US | disclosed |
| US-9938259-B2 | Therapeutic compositions and related methods of use | AGIOS PHARMACEUTICALS, INC. (US) | 2018-04-10 | — | — | US | disclosed |
| US-20170283401-A1 | THERAPEUTIC COMPOSITIONS AND RELATED METHODS OF USE | AGIOS PHARMACEUTICALS, INC. | 2017-10-05 | — | — | US | disclosed |
| US-20170283401-A1 | THERAPEUTIC COMPOSITIONS AND RELATED METHODS OF USE | AGIOS PHARMACEUTICALS, INC. | 2017-10-05 | — | — | US | disclosed |
| US-20170283401-A1 | THERAPEUTIC COMPOSITIONS AND RELATED METHODS OF USE | AGIOS PHARMACEUTICALS, INC. | 2017-10-05 | — | — | US | disclosed |
| US-9657004-B2 | Pyruvate kinase M2 modulators, therapeutic compositions and related methods of use | AGIOS PHARMACEUTICALS, INC (US) | 2017-05-23 | — | — | US | disclosed |
| US-9657004-B2 | Pyruvate kinase M2 modulators, therapeutic compositions and related methods of use | AGIOS PHARMACEUTICALS, INC (US) | 2017-05-23 | — | — | US | disclosed |
| US-9657004-B2 | Pyruvate kinase M2 modulators, therapeutic compositions and related methods of use | AGIOS PHARMACEUTICALS, INC (US) | 2017-05-23 | — | — | US | disclosed |
| US-20160052917-A1 | PYRUVATE KINASE M2 MODULATORS, THERAPEUTIC COMPOSITIONS AND RELATED METHODS OF USE | AGIOS PHARMACEUTICALS, INC | 2016-02-25 | — | — | US | disclosed |
| US-20140323729-A1 | PYRUVATE KINASE M2 MODULATORS, THERAPEUTIC COMPOSITIONS AND RELATED METHODS OF USE | AGIOS PHARMACEUTICALS, INC (US) | 2014-10-30 | — | — | US | disclosed |
| US-8742119-B2 | Pyruvate kinase M2 modulators, therapeutic compositions and related methods of use | AGIOS PHARMACEUTICALS, INC. (US) | 2014-06-03 | — | — | US | disclosed |
| US-8742119-B2 | Pyruvate kinase M2 modulators, therapeutic compositions and related methods of use | AGIOS PHARMACEUTICALS, INC. (US) | 2014-06-03 | — | — | US | disclosed |
| US-8742119-B2 | Pyruvate kinase M2 modulators, therapeutic compositions and related methods of use | AGIOS PHARMACEUTICALS, INC. (US) | 2014-06-03 | — | — | US | disclosed |
| US-20120122885-A1 | PYRUVATE KINASE M2 MODULATORS, THERAPEUTIC COMPOSITIONS AND RELATED METHODS OF USE | AGIOS PHARMACEUTICALS, INC. | 2012-05-17 | — | — | US | disclosed |
| US-20120122885-A1 | PYRUVATE KINASE M2 MODULATORS, THERAPEUTIC COMPOSITIONS AND RELATED METHODS OF USE | AGIOS PHARMACEUTICALS, INC. | 2012-05-17 | — | — | US | disclosed |
| US-20120122885-A1 | PYRUVATE KINASE M2 MODULATORS, THERAPEUTIC COMPOSITIONS AND RELATED METHODS OF USE | AGIOS PHARMACEUTICALS, INC. | 2012-05-17 | — | — | US | disclosed |
| CN-102448951-A | Pyruvate kinase M2 modulators, therapeutic compositions, and related methods of use | AGIOS PHARMACEUTICALS INC | 2012-05-09 | — | — | CN | disclosed |
| EP-2417123-A2 | THERAPEUTIC COMPOSITIONS AND RELATED METHODS OF USE | Agios Pharmaceuticals, Inc. (US) | 2012-02-15 | — | — | EP | disclosed |
| WO-2010118063-A2 | THERAPEUTIC COMPOSITIONS AND RELATED METHODS OF USE | AGIOS PHARMACEUTICALS, INC. (US) | 2010-10-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140323729-A1 | PYRUVATE KINASE M2 MODULATORS, THERAPEUTIC COMPOSITIONS AND RELATED METHODS OF USE | PDK2, PDK1, PDK3 | MEN1 3892/4885KMT2A 625/4885GABRA1 3063/4885 |
| US-20160052917-A1 | PYRUVATE KINASE M2 MODULATORS, THERAPEUTIC COMPOSITIONS AND RELATED METHODS OF USE | PDK2, PDK1, PDK3 | MEN1 3892/4885KMT2A 625/4885GABRA1 3063/4885 |
| US-20170283401-A1 | THERAPEUTIC COMPOSITIONS AND RELATED METHODS OF USE | PDK2, PDK1, PDK3 | MEN1 3936/4885KMT2A 880/4885GABRA1 3594/4885 |
| US-20120122885-A1 | PYRUVATE KINASE M2 MODULATORS, THERAPEUTIC COMPOSITIONS AND RELATED METHODS OF USE | PDK2, PDK1, PDK3 | MEN1 3892/4885KMT2A 625/4885GABRA1 3063/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.